Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17798120 | 1.00 | BRD4 (0.53) | BRD4CREBBPEP300NR3C1LMNA | |
| SCHEMBL17798163 | 0.90 | BRD4 (0.64) | BRD4CREBBPEP300NR3C1 | |
| SCHEMBL29921009 | 0.90 | BRD4 (0.64) | BRD4CREBBPEP300NR3C1 | |
| SCHEMBL17798103 | 0.81 | BRD4 (0.59) | BRD4CREBBPEP300 | |
| SCHEMBL29920806 | 0.81 | BRD4 (0.59) | BRD4CREBBPEP300 | |
| SCHEMBL17797991 | 0.74 | BRD4 (0.50) | BRD4CREBBPEP300 | |
| SCHEMBL15816001 | 0.73 | BRD4 (0.55) | BRD4CREBBPEP300LMNA | |
| SCHEMBL17798077 | 0.71 | GRIN1 (0.58) | BRD4 | |
| SCHEMBL17798085 | 0.70 | BRD4 (0.55) | BRD4CREBBPEP300NR3C1 | |
| SCHEMBL15815665 | 0.70 | SMN1; SMN2 (0.46) | BRD4CREBBPEP300LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446306-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 24/4885EP300 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.